Farther Finance Advisors LLC Sells 151 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Farther Finance Advisors LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 573 shares of the biopharmaceutical company’s stock after selling 151 shares during the period. Farther Finance Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $409,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of REGN. Amundi grew its stake in shares of Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock valued at $1,138,074,000 after buying an additional 487,489 shares during the period. Proficio Capital Partners LLC increased its holdings in Regeneron Pharmaceuticals by 92,865.3% during the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock worth $156,284,000 after purchasing an additional 219,162 shares in the last quarter. Worldquant Millennium Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $127,489,000. KBC Group NV grew its holdings in Regeneron Pharmaceuticals by 296.7% during the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after buying an additional 102,198 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $65,180,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent analyst reports. Wells Fargo & Company reduced their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Citigroup lowered their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. BMO Capital Markets dropped their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 4th. Sanford C. Bernstein lowered their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Finally, Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Trading Up 1.7 %

Shares of NASDAQ REGN opened at $678.42 on Tuesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The firm has a market cap of $74.17 billion, a PE ratio of 17.72, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The business has a fifty day simple moving average of $694.15 and a two-hundred day simple moving average of $827.65. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business earned $11.86 EPS. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.52%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.